Sutter Health Hospitals Deploy Wearable Ultrasound Tech to Personalize Fluid Management for Sepsis
Major California health system leads adoption of FloPatch, a device offering clinical teams real-time data to reduce the risk of giving too much or too little fluid
Article content
Article content
both of which can lead to serious complications
Article content
SACRAMENTO, Calif. & LOS ANGELES — Sutter Health, an integrated not-for-profit healthcare system based in Northern California, and Flosonics Medical today announced an expansion of the deployment of FloPatch, the first wireless wearable Doppler ultrasound device, across multiple hospital sites to support more precise and timely intravenous (IV) fluid management. This multisite deployment includes Sutter's Alta Bates Summit Medical Center, Summit Campus in Oakland and Sutter Santa Rosa Regional Hospital in Sonoma County. Implementations span the Emergency Department, Intensive Care Unit, Medical-Surgical Unit and Telemetry Unit. With these additions, six Sutter hospital campuses have now deployed FloPatch over the past year and include Sutter's Eden Medical Center in Castro Valley, Sutter's CPMC in San Francisco at CPMC Van Ness, Davies and Mission Bernal Campuses.
IV fluid overload is a common complication in emergency and intensive care settings, in part because predicting a patient's response to fluids is complex. Individual needs can vary widely and shift quickly during critical illness. In studies of patients with sepsis and septic shock – a life-threatening condition caused by the body's overwhelming response to infection – nearly one-third were found to be fluid unresponsive¹. Without early identification of fluid unresponsiveness, patients may receive excessive fluids, increasing their risk of serious complications such as pulmonary edema, where fluid accumulates in the lungs. By some estimates, fluid overload can extend the average hospital stay by three days and increase healthcare costs by more than $15,000 per patient².
Article content
FloPatch is an FDA-cleared, wearable device that provides clinicians with a fast and non-invasive way to perform hemodynamic assessments, measuring a patient's heart and blood flow response to IV fluids to help guide personalized fluid therapy. Clinical studies have shown that dynamic fluid assessments can reduce the need for mechanical ventilation and renal replacement therapy ³,⁴, decrease ICU length of stay⁴, and are associated with lower mortality⁵.
Article content
'Our previous method of assessing fluid responsiveness was cumbersome and time-consuming. We often had to pull ICU nurses to perform evaluations in other units, which was disruptive and inefficient,' said Dr. Nader Emami, ICU medical director at Sutter Santa Rosa Regional Hospital. 'FloPatch streamlines the process with a simple, wearable device that empowers any member of the care team to perform this essential assessment faster and easier.'
Article content
'In emergency care, we often treat patients with complex needs, including people with sepsis,' said Dr. John Skovran, Emergency Department medical director at Sutter's Alta Bates Summit Medical Center, Summit Campus. 'We need a fast, reliable way to determine whether they'll benefit from fluids or be harmed by them. FloPatch gives us that clarity at the bedside in minutes, helping us make confident, timely decisions.'
Article content
Joe Eibl, chief executive officer and co-founder of Flosonics Medical, noted: 'Sutter Health's multisite adoption of FloPatch reflects a growing recognition that wearable, real-time technologies play a transformative role in patient care. It's a great example of how forward-thinking health systems are meeting critical challenges with innovation.'
Article content
Sutter Health prioritized staff training and thoughtfully integrated FloPatch into clinical workflows to make it a seamless part of care in intensive care and emergency medicine departments.
Article content
About Sutter Health:
Article content
Sutter Health is a not-for-profit healthcare system dedicated to providing comprehensive care throughout California. Committed to health equity, community partnerships, and innovative, high-quality patient care, Sutter Health is pursuing a bold new plan to reach more people and make excellent healthcare more connected and accessible. Currently serving more than 3.5 million patients, thanks to our dedicated team of more than 60,500 employees and clinicians, and 14,000+ physicians and advanced practice clinicians, with a unified focus on expanding care to serve more patients.
Article content
Sutter delivers exceptional and affordable care through its hospitals, medical groups, ambulatory surgery centers, urgent care clinics, telehealth, home health, and hospice services. Dedicated to transforming healthcare, at Sutter Health, getting better never stops.
Article content
Learn more about how Sutter Health is transforming healthcare at sutterhealth.org and vitals.sutterhealth.org.
Article content
About Flosonics Medical:
Article content
Flosonics Medical is a medical device company engaged in the research and development of innovative ultrasound technology. Founded in 2015, the company's mission is to improve patient care and the practice of medicine through technology-enabled solutions and groundbreaking clinical research. For more information, please visit
Article content
.
Article content
¹ Hernández G, Ospina‑Tascón GA, Damiani LP, et al; ANDROMEDA‑SHOCK Investigators. Effect of a resuscitation strategy targeting peripheral perfusion status vs serum lactate levels on 28‑day mortality among patients with septic shock: the ANDROMEDA‑SHOCK randomized clinical trial. JAMA. 2019 Feb 19;321(7):654–664. doi:10.1001/jama.2019.0071
Article content
Article content
³ Douglas IS, Alapat PM, Corl KA, Exline MC, Forni LG, Holder AL, et al. Fluid Response Evaluation in Sepsis Hypotension and Shock: A Randomized Clinical Trial. Chest. 2020 Oct;158(4):1431–1445. doi:10.1016/j.chest.2020.04.025
Article content
Article content
⁴ Latham HE, Bengtson CD, Satterwhite L, et al. Stroke volume–guided resuscitation in severe sepsis and septic shock improves outcomes. J Crit Care. 2017 Dec;42:42–46. doi:10.1016/j.jcrc.2017.06.028
Article content
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Media Contacts:
Article content
Jamie Gray, Flosonics Medical,
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vancouver Sun
2 hours ago
- Vancouver Sun
U.S. Batten disease experts who lobbied B.C. to reinstate drug in Charleigh Pollock case had relationships with drug company
Almost all the U.S. research experts the B.C. government leaned on to make a decision to reinstate a $800,000-a-year drug treatment for a 10-year-girl have, or had, relationships with the pharmaceutical company that manufacturers the drug or foundations that advocate for treatment, a Postmedia examination has found. The province's decision went against its own 58-member advisory committee. Of the 12 physicians and one neuroscientist who signed a letter sent to B.C. Health Minister Josie Osborne calling on treatment to be reinstated, eight of the signatories have declared conflicts in the past five years in papers written for scientific journals or for public presentations because they have consulted for, been paid by, or received grants from California-based BioMarin Pharmaceutical Inc. Another doctor reported being a consultant for BioMarin for four years on a resumé posted online and was paid by BioMarin to be on a medical podcast. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. BioMarin manufactures Brineura used to treat Batten disease, the rare incurable neurodegenerative condition that 10-year-old B.C. girl Charleigh Pollock has. Three other doctors who signed the letter have relationships with foundations that advocate and raise money for Batten disease research. The Postmedia examination also found that one of the U.S. doctors that signed the letter owns shares in BioMarin, two have been quoted in BioMarin news releases and three former BioMarin employees sit on one of the U.S.-based Batten research foundations. Experts in bioethics and pharmaceutical policy say the conflict-of-interest revelations raise questions on why the B.C. government overruled its own advisory committee, why it depended on the opinions of U.S. doctors with relationships to BioMarin, and whether it took those conflict-of-interest relationships into consideration. 'I want to suggest that the British Columbia Ministry of Health was handling this case in an ethically justifiable way and has been sidetracked by the lobbying efforts of the Batten disease patient advocacy groups and the patient herself and the doctors whose careers stand to benefit from licensing and prescribing this drug,' said Arthur Schafer, a University of Manitoba professor with a speciality in bioethics and founder of the school's centre for professional and applied ethics. In an emailed statement from communications manager Amy Crofts, the B.C. Ministry of Health said they 'can confirm that government was aware that some of the U.S. experts have conflicts of interest.' Officials noted the conflicts were required to be declared when publishing peer-reviewed research on Batten disease, including the initial clinical trials on Brineura that were funded by BioMarin and used by Canada's Drug Agency in 2019 to establish the discontinuation criteria. Health officials did not respond to questions on whether the government considered the conflicts of interest in their assessment and how it weighed these conflicts against the advice of its own adviser group. Osborne was not made available for an interview. Initially, the B.C. government backed its advisory committee's decision to halt treatment to the 10-year-old girl after six years. The advisory committee said they recommended stopping treatment because discontinuation criteria was met, and beyond which the benefits versus risks of the drug were not believed to be favourable. The U.S. doctors sent a letter — under a Batten disease support and research association designation — outlining their concerns and calling for the girl's treatment to continue. Osborne, the health minister, said the province reversed its decision because of the letter. 'The letter I received today from the Batten disease experts confirms there is a significant disagreement between health experts on Brineura, and it is not acceptable that Charleigh and her family suffer as a result of that disagreement about the use of Brineura for Batten disease,' Osborne said last month. Following the reversal, 10 members of the advisory committee quit and B.C. Premier David Eby has now called for a review and overhaul of the decision process. Schafer, who has been studying biomedical conflicts of interest for more than 20 years, said he was not surprised to learn the U.S. letter signatories had relationships with the drug company that produced the drug and that they recommended its continued use. He said he believes the B.C. government would have been fully aware of the conflicts of interests held by the U.S. doctors who signed the letter, as these relationships are 'standard procedure.' Schafer, who formerly worked as an ethics consultant for the Winnipeg Regional Health Authority, said he believes the B.C. government capitulated and caved to pressure, as he believes most Canadian provincial governments would. 'And I think the resulting decision is not morally justifiable,' he said. Schafer noted the effectiveness of these expensive rare-disease drugs is often unproven, underscoring the importance for governments to have independent expert advice when making difficult decisions in the face of emotion, public pressure and scarce resources. Other experts have made similar observations. Pierre-Marie David, a professor in the faculty of pharmacy at the University of Montreal who has been researching access to exceptional drugs, said a key to making these decisions is building trust in provincial health agencies, particularly given there is a large pipeline of these expensive drugs with uncertain effectiveness for rare diseases, which means more difficult decisions and increasing costs. 'If we have trust in the decision of a public agency, we should stick to it,' said David. He said he did not believe provinces and Canada should be turning for advice to the U.S. health system, whether the doctors there are right or wrong, or have a conflict of interest or not, because they do not have a public health care system like Canada's. 'They have no lessons to tell us here,' said David. The relationships of some of the U.S. letter signatories to BioMarin are laid out in conflict-of-interest and disclosure statements in scientific journals. For example, a 2024 editorial Dr. Raymond Wang wrote for the journal Neurology includes a 'disclosure' that says he receives research funding from, has received speaking honorariums from, and owns equity in BioMarin Pharmaceuticals, which manufacturers Brineura. Wang is director of the Batten Disease Center for Excellence at Children's Hospital of Orange County in California. A 2024 Lancet Neurology journal article co-written by Dr. Emily de los Reyes includes a conflict-of-interest statement that notes she received 'salary support' from BioMarin for herself and her research personnel. She also received honorariums and travel support. De los Reyes is the chair of the Batten Disease Centers of Excellence program and director of the Batten Disease Center of Excellence at Nationwide Children's Hospital in Columbus, Ohio. A 2022 Journal of Inherited Metabolic Disease paper co-authored by Dr. Erika Augustine, who is the director of the Batten Disease Centre of Excellence at the Kennedy Krieger Institute in Baltimore, notes in a conflict-of-interest statement that she received compensation as a consultant for BioMarin and other pharmaceutical companies. Postmedia reached out by email to these doctors to ask questions about the conflict-of-interest disclosures, but did not receive a reply. In a written response to Postmedia questions, Amy Fenton Parker, president of the Batten Disease Support and Research Association, said questions of funding from drug companies should be posed to each research and clinical treatment group. 'In all scientific presentations, both groups are required to make disclosures about any funding or conflicts of interest,' noted Parker. She noted the centres of excellence do not receive funding from industry partners through the association. There are a number of Batten disease organizations that co-operate and partner to advocate for, and help fund, research for treatments. The Batten Disease Support and Research Association manages the centres of excellence program, under which the U.S. doctors who signed the letter operate. That association has three former BioMarin employees on its board of directors , including vice-chair Barbara Wuebbels. Another group, the Beyond Batten Disease Foundation, has raised $35 million to help fund research to find treatments and has partnered with the Batten Disease Support and Research Association. The research association has several chapters around the world, including in Canada. The 10-year-old B.C. girl's mother, Jori Fales, is on the board of directors of the Canadian chapter, according to the latest filing of the group for registered charities in Canada. ghoekstra@
Globe and Mail
a day ago
- Globe and Mail
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today
Key Points Weight loss drugs are big news, and Viking has one in development in both injectable and oral form. Investors are eagerly awaiting trial results later this year. 10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: VKTX) investors have seen a handsome return over the past three years, and this demonstrates that the real battle over biopharmaceutical stocks is won in the lab and clinical trials. Viking Therapeutics doesn't have a commercial product on the market yet and has never generated a dollar in revenue. Yet, it's made many investors wealthy. One thousand dollars invested three years ago is now worth an incredible $10,640 as of Aug. 11. Viking Therapeutics: The best may be yet to come The excitement around the stock centers on its lead development compound, VK2735. It's a GLP-1/GIP dual agonist for the treatment of obesity. Vikings VK2735 is following in the footsteps of Eli Lilly's GLP-1/GIP dual agonist tirzepatide (branded as Zepbound), and investors are hoping VK2735 can achieve similar levels of success. Where is this promising drug now VK2735 is in phase 3 trials in subcutaneous (injection) form, with results probably not due until 2027, and, arguably more excitingly, it's in phase 2 trials in an oral form. The latter has obvious benefits of convenience and comfort for patients, and management expects to report on the phase 2 trial this year. Investors have high hopes, as the phase 2 subcutaneous trial resulted in up to 88% of patients experiencing more than 10% weight loss. The phase 1 trials in oral form were also impressive (remember that phase 1 trials are fundamentally exploratory and often aim to understand safety and tolerability), with a mean weight loss of 8.2% after 28 days of dosing. These results are enough to encourage Viking investors that VK2735 could prove to be a hugely successful compound, and the results of the latest tests of the oral form are eagerly anticipated, not least by potential larger pharmaceutical companies that may try to buy the company and take VK2735 (oral) through phase 3. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025
Globe and Mail
5 days ago
- Globe and Mail
Golden Years Home Care Continues Mission to Transform Lives with Premier Senior Home Care in San Diego, CA
A cheerful caregiver shares a lighthearted moment with a smiling senior holding a phone, perfectly capturing the spirit of Golden Years Home Care Continues Mission to Transform Lives with Premier Senior Home Care in San Diego, CA-providing compassionate, personalized support that fosters independence, dignity, and joy in the comfort of home. Golden Years Home Care reaffirms its mission to provide premier senior home care in San Diego, CA, helping seniors age with dignity and comfort at home. Through personalized care plans, compassionate companionship, and assistance with daily needs, the agency supports independence while easing the burden on families. Highly trained caregivers deliver safety, emotional support, and peace of mind, ensuring seniors enjoy a higher quality of life in familiar surroundings. San Diego, CA - Golden Years Home Care today reaffirms its unwavering commitment to the senior community of San Diego. Under the leadership of Ken Ballard, the agency continues its mission to transform the lives of elderly residents and their families through dedicated and personalized in-home care services. This ongoing initiative addresses the critical need for reliable support, allowing seniors to age with dignity and comfort in their own homes. As the population of seniors grows, many families find themselves navigating the complexities of providing adequate care for their aging loved ones. The desire for seniors to remain in a familiar, cherished environment is often met with the challenge of ensuring their safety, health, and well-being. Golden Years Home Care steps into this gap, offering a structured yet compassionate solution that alleviates the pressure on family caregivers and enhances the quality of life for seniors. One of the most significant benefits of the services provided by Golden Years Home Care is the profoundly personalized approach. Recognizing that every individual has unique needs and preferences, the agency develops customized care plans in close consultation with the senior and their family. This tailored strategy for senior care at home in San Diego, CA ensures that clients maintain their independence and daily routines while receiving the precise level of support they require, from companionship and meal preparation to mobility assistance. Furthermore, the service provides invaluable peace of mind for families. Entrusting the care of a loved one to a professional is a major decision, and Golden Years Home Care addresses this with a team of highly trained, vetted, and compassionate caregivers. Families can rest assured that their loved ones are not only safe but are also benefiting from social interaction and emotional support, combating the loneliness and isolation that can often affect seniors. This comprehensive approach is the hallmark of quality Senior Home Care in San Diego, CA. "Our goal has always been to build a support system that feels like family," said Ken Ballard, founder of Golden Years Home Care. "We see the challenges families face every day, and we want them to know they are not alone in this journey. Our team is here to provide the compassionate, professional care that allows their loved ones to age gracefully and safely in the comfort of their own home." Golden Years Home Care continues to be a pillar of support in the San Diego community, dedicated to fostering independence and delivering exceptional care. The agency's mission is rooted in the belief that every senior deserves to live a fulfilling and dignified life, regardless of age or health challenges. For more information about Golden Years Home Care and their senior home care in San Diego, CA, please visit their website at About Golden Years Home Care: Golden Years Home Care is a leading provider of senior care at home in San Diego, CA. Founded on the core principles of compassion, dignity, and respect, the agency is dedicated to helping seniors live independently and safely in the comfort of their own homes. By offering customized care plans, their team of highly trained and vetted caregivers is committed to enhancing the quality of life for every client. Golden Years Home Care serves as a trusted partner for families, delivering peace of mind and ensuring their loved ones receive the exceptional support they deserve. Media Contact Company Name: Golden Years Home Care (San Diego, CA) Contact Person: Ken Ballard Email: Send Email Phone: (916) 333-0383 Address: 301 SPRUCE ST, STE 101 City: San Diego State: California 92103-5626 Country: United States Website:
